Skip to main content

Recombinant Human Galectin-3C Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10110-GA

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
10110-GA-050

Key Product Details

Source

HEK293

Accession #

Structure / Form


Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human Galectin-3C protein
Gly108-Ile250

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Gly108

Predicted Molecular Mass

16 kDa

SDS-PAGE

14-18 kDa, reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Human Integrin alpha 5 beta 1 Recombinant Human Integrin  alpha5 beta1 (Catalog # 3230-A5) is immobilized at 1 µg/mL (100 µL/well), the concentration of Recombinant Human Galectin-3C that produces 50% of the optimal binding response is 1-6 μg/mL.

Scientific Data Images for Recombinant Human Galectin-3C Protein, CF

Recombinant Human Galectin-3C Protein Binding Activity

Recombinant Human Galectin-3C Protein Binding Activity

When Recombinant Human Integrin a5 beta1 (Catalog # 3230-A5) is coated at 1 µg/mL (100 µL/well), Recombinant Human Galectin-3C (Catalog # 10110-GA) binds with an ED50 of 1-6 µg/mL
Recombinant Human Galectin-3C Protein SDS-PAGE

Recombinant Human Galectin-3C Protein SDS-PAGE

2 μg/lane of Recombinant Human Galectin‑3C was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 14-18 kDa.

Formulation, Preparation and Storage

10110-GA
Formulation Lyophilized from a 0.2 μm filtered solution in HEPES, NaCl, TCEP, PEG and Trehalose.
Reconstitution Reconstitute at 500 μg/mL in water.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Galectin-3C

Human Galectin-3, also known as Mac-2, L29, CBP35, and epsilon BP, is classified as a chimeric member of the Galectin superfamily and contains one carbohydrate recognition domain (CRD) linked to a nonlectin domain (1, 2). The truncated form, Galectin-3C, which consists of the carboxy-terminal amino acid residues of Galectin-3 and lacks the N-terminal domain, has been shown to inhibit tumor growth and metastasis (3, 4). Within this region, human Galectin-3C shares 87% and 83% amino acid (aa) sequence identity with mouse and rat Galectin-3C, respectively. Galectin-3C has been found to interact with Integrin beta 1 in Hela cell lateral mobility assays (5). It can also be found endogenously attached to cell surface of neutrophils (6). Galectin-3C has been shown to enhance the activity of cancer therapy drugs as well as inhibiting tubule formation during angiogenesis (3).

References

  1. Robertson, M.W. et al. (1990) Biochemistry 29:8093.
  2. Elola, M.T. et al. (2007) Cell. Mol. Life Sci. 64:1679.
  3. Mirandola, L. et al. (2011) PloS One 6:e21811.
  4. John, C.M. et al. (2003) Clin. Cancer Res. 9:2374.
  5. Yang, E.H. et al. (2017) PLoS ONE 12:e0184378.
  6. Sundqvist, M. et al. (2018) J. Leukoc. Biol. 103:341.

Long Name

Galectin-3, C-Terminus

Entrez Gene IDs

3958 (Human); 16854 (Mouse)

Gene Symbol

LGALS3

UniProt

Additional Galectin-3C Products

Product Documents for Recombinant Human Galectin-3C Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human Galectin-3C Protein, CF

For research use only

Loading...
Loading...
Loading...
Loading...